Examiner Ratings For Lexicon Pharmaceuticals (NASDAQ:LXRX)
Today, Cowen and Company emphasized its Market Perform rating on Lexicon Pharmaceuticals (NASDAQ:LXRX).
There are 2 hold appraisals, 5 purchase evaluations on the stock.
The present accord rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) is Buy (Score: 2.71) with an agreement target cost of $24.50 per share, a potential 61.40% upside.
Some late expert evaluations incorporate
12/23/2016-Cowen and Company Reiterated Rating of Market Perform.
12/22/2016-Wedbush Reiterated Rating of Outperform.
11/2/2016-HC Wainwright Reiterated Rating of Buy.
9/12/2016-Needham and Company LLC Reiterated Rating of Buy.
5/5/2016-JPMorgan Chase and Co. Repeated Rating of Hold.
Profit data for Lexicon Pharmaceuticals (NASDAQ:LXRX)
.
On 6/6/2016 James F Tessmer, VP, sold 1,500 with a normal share cost of $15.00 per share and the aggregate exchange adding up to $22,500.00.
On 5/23/2016 James F Tessmer, VP, sold 6,000 with a normal share cost of $13.00 per share and the aggregate exchange adding up to $78,000.00.
On 12/12/2014 C.V. Invus, Director, purchased 150,000 with a normal share cost of $0.88 per share and the aggregate exchange adding up to $132,000.00.
On 12/10/2014 C.V. Invus, Director, purchased 315,896 with a normal share cost of $0.90 per share and the aggregate exchange adding up to $284,306.40.
On 11/26/2014 International S.C.A. Artal, Director, purchased 149,253,731 with a normal share cost of $1.01 per share and the aggregate exchange adding up to $150,746,268.31.
On 10/23/2012 International S.C.A. Artal, Director, purchased 3,000,000 with a normal share cost of $2.25 per share and the aggregate exchange adding up to $6,750,000.00.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Dictionary Pharmaceuticals, Inc. (Dictionary) is a biopharmaceutical organization. The Company concentrates on the advancement of medicines for human ailment. The Company is occupied with the improvement of two medication applicants: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally conveyed little atom sedate competitor, as a treatment for carcinoid disorder. LX1032 restrains tryptophan hydroxylase (TPH), which is an orally-conveyed little particle intensify that the Company is producing for the treatment of carcinoid disorder. Sotagliflozin, or LX4211, which is an orally-conveyed little atom aggravate that the Company is producing for the treatment of sort 1 and sort 2 diabetes mellitus. LX2761 is an orally-conveyed little particle compound for the treatment of diabetes. LX9211 is an orally-conveyed little atom compound for the treatment of neuropathic agony. The Company's different projects incorporate LX1033, LX2931 and LX7101.
Late Trading Activity for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Shares of Lexicon Pharmaceuticals shut the past exchanging session at 15.18 up +0.94 6.60% with 1,025,045 shares exchanging hands.
Today, Cowen and Company emphasized its Market Perform rating on Lexicon Pharmaceuticals (NASDAQ:LXRX).
There are 2 hold appraisals, 5 purchase evaluations on the stock.
The present accord rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) is Buy (Score: 2.71) with an agreement target cost of $24.50 per share, a potential 61.40% upside.
Some late expert evaluations incorporate
12/23/2016-Cowen and Company Reiterated Rating of Market Perform.
12/22/2016-Wedbush Reiterated Rating of Outperform.
11/2/2016-HC Wainwright Reiterated Rating of Buy.
9/12/2016-Needham and Company LLC Reiterated Rating of Buy.
5/5/2016-JPMorgan Chase and Co. Repeated Rating of Hold.
Profit data for Lexicon Pharmaceuticals (NASDAQ:LXRX)
.
On 6/6/2016 James F Tessmer, VP, sold 1,500 with a normal share cost of $15.00 per share and the aggregate exchange adding up to $22,500.00.
On 5/23/2016 James F Tessmer, VP, sold 6,000 with a normal share cost of $13.00 per share and the aggregate exchange adding up to $78,000.00.
On 12/12/2014 C.V. Invus, Director, purchased 150,000 with a normal share cost of $0.88 per share and the aggregate exchange adding up to $132,000.00.
On 12/10/2014 C.V. Invus, Director, purchased 315,896 with a normal share cost of $0.90 per share and the aggregate exchange adding up to $284,306.40.
On 11/26/2014 International S.C.A. Artal, Director, purchased 149,253,731 with a normal share cost of $1.01 per share and the aggregate exchange adding up to $150,746,268.31.
On 10/23/2012 International S.C.A. Artal, Director, purchased 3,000,000 with a normal share cost of $2.25 per share and the aggregate exchange adding up to $6,750,000.00.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Dictionary Pharmaceuticals, Inc. (Dictionary) is a biopharmaceutical organization. The Company concentrates on the advancement of medicines for human ailment. The Company is occupied with the improvement of two medication applicants: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally conveyed little atom sedate competitor, as a treatment for carcinoid disorder. LX1032 restrains tryptophan hydroxylase (TPH), which is an orally-conveyed little particle intensify that the Company is producing for the treatment of carcinoid disorder. Sotagliflozin, or LX4211, which is an orally-conveyed little atom aggravate that the Company is producing for the treatment of sort 1 and sort 2 diabetes mellitus. LX2761 is an orally-conveyed little particle compound for the treatment of diabetes. LX9211 is an orally-conveyed little atom compound for the treatment of neuropathic agony. The Company's different projects incorporate LX1033, LX2931 and LX7101.
Late Trading Activity for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Shares of Lexicon Pharmaceuticals shut the past exchanging session at 15.18 up +0.94 6.60% with 1,025,045 shares exchanging hands.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.